Presentations at Scientific Meetings

As experts in the liver disease medical science sector, HepQuant’s Dr. Everson and other team members have been featured speakers and presenters at a wide range of international liver conferences.

Recent Events

Rocky Mountain Life Sciences Investor and Partnering Conference | Vail, CO | Sep. 13-14, 2022

The American College of Clinical Pharmacology® (ACCP) Annual Meeting |Bethesda, MD | Sept 25-27

  • Poster: Advantages of HepQuant SHUNT over Child-Pugh Classification in Defining Hepatic Impairment for Pharmacokinetics Studies: Experience with Ampreloxetine

Digestive Disease Week DDW® 2022 | May 21 – 24, 2022

  • Poster Presentation: The HepQuant’s Disease Severity Index (HepQuant DSI™) Outperforms Child-Pugh (CP) Classification in Quantifying Hepatic Impairment for Prediction of Drug Pharmacokinetics (PK) in Chronic Liver Disease 
  • Poster Presentation: The HepQuant Shunt Disease Severity Index (HepQuant DSI™) Can Aid the Decision to Avoid Endoscopic Screening or Surveillance for Varices Needing Treatment

NASH-TAG Conference | January 6 – 8, 2022

  • Poster Presentation: HMG-CoA Reductase Inhibitors (Statins) and Metformin are Associated With Preservation of Hepatic Function and Less Portal-Systemic Shunting in Advanced Chronic Liver Disease (CLD)

NASH Summit 2021 | November 29-December 2 | Sponsor

  • Oral PresentationHepQuant: Progressing towards a Sensitive and Reliable Endpoint for Treatment Efficacy.  Greg Everson, MD.
    • New Data from Clinical Trials (response to new pharma therapy, reproducibility, progression to decomp in cirrhosis, portal hypertension) 
    • Pivotal Study and Regulatory Progress
    • Anticipated Timelines for Clinical Trial and Commercial Scale-up

AASLD The Liver Meeting | November 12-15, 2021

  • Poster: BI 685509 Improves Hepatic Function in Subjects with Child-Pugh A Cirrhosis and a Liver Stiffness Measurement of >15 KPA: Results from the HepQuant SHUNT Test. Lawitz EJ, Ertle J, Schoelch C, Gawshaw I, Helmke SM and Everson GT.  {Lawitz et al: Hepatology 2021, Volume 74, Number 1 (Suppl), 1238A-1239A}
  • Poster: The HepQuant SHUNT Test Predicts the Likelihood of Finding Esophageal Varices and Particularly Large Varices at Endoscopy. Shiffman ML, Leise MD, Reddy KR, Hellstern PA, Hassanein T, Qureshi K, Mena E, Smith AD, Kittelson JM, Helmke SM, Everson GT, HepQuant, and SHUNT-V Investigators Group. {Shiffman et al: Hepatology 2021, Volume 74, Number 1 (Suppl), 1264A-1265A}
  • Oral Presentation: Treatment with HMG-CoA Reductase Inhibitors (Statins) is Associated with Preservation of Hepatic Function in Advanced Chronic Liver Disease (CLD): Results from the SHUNT-V Study. Rahimi RS, Lucas KJ, Weinberg EM, Kayali Z, Bhagat VK, Keaveny AP, Mantry PS, Smith AD, Kittelson JM, Helmke SM, Everson GT, and SHUNT-V Investigators Group. {Rahimi et al:  Hepatology 2021, Volume 74, Number 1 (Suppl), 98A-99A}

Dr Everson presenting at Scientific Meeting

American Heart Association (AHA) Annual Meeting | November 13-15, 2021

  • Oral Presentation: Clinical and Laboratory Correlates of Impaired Cholate Clearance in the Adult Fontan.  Kim YY, Saef J, Everson G, Helmke S, Carducci J, Glatz AC, Partington SL, Ruckdeschel E, Rychik J, Hoteit MA. {Kim et al: Circulation 2021 Volume 144, Suppl_1, A14429} (See Abstract)

EASL International Liver Congress | June 23-26, 2021

AASLD/FDA DILI Conference Drug Induced Liver Injury| Virtual Conference | April 20 – 22, 2021 | “New Developments, Innovative Tools and Assessment Strategies in Patients with Underlying Liver Disease or Cancer and in the Setting of the Covid-19 Pandemic” | Gregory T. Everson, MD, FAASLD presented “Non-invasive Quantitative Liver Tests for Disease Activity and Fibrosis: Can They Reliably Guide Optimal Treatment Regimens During the Progression of CLD.”

  • Poster: The Disease Severity Index (DSI) from the HepQuant SHUNT Test Sets the Stage for Predicting Drug Pharmacokinetics (PK) in Chronic Liver Disease

2021 AASLD/FDA DILI Conference Drug Induced Liver Injury | Virtual Conference | April 20 – 22, 2021 | Conference Website

Poster: The Disease Severity Index (DSI) from the HepQuant SHUNT Test Sets the Stage for Predicting Drug Pharmacokinetics (PK) in Chronic Liver Disease

NASH Summit 2020 | December 14-16, 2020 | Virtual Conference | Conference Website

Oral Presentation: Complimentary Diagnostics for Drug Development and the Clinic

AASLD: The Liver Meeting Digital Experience | November 13-16, 2020 | Conference Website

Poster: The HepQuant SHUNT Test of Global Liver Function and Physiology Identifies the Patients with Advanced Fibrosis or Compensated Cirrhosis Who are At-Risk for Hepatocellular Carcinoma

Poster: Diagnostic Performance of The HepQuant Shunt Test in Prediction of Large Esophageal Varices in Well-Compensated Fibrosis or Cirrhosis Due to Chronic Hepatitis C

Oral Presentation by Baylor – AASLD: The Liver Meeting Digital Experience | November 13-16, 2020 | Conference Website

Presentation: “Dual Cholate Test and Prediction of Decompensation, Liver Transplantation, Death and Hospitalization in Cirrhosis: A Prospective Study.

Digestive Disease Week (DDW) | Virtual | May 3, 2020 | Conference Website

  • Abstract: “Predicting Decompensation, Death, or Liver Transplantation in Cirrhosis by Using a Non-Invasive Liver Function Test (HepQuant SHUNT)”, an oral Presentation

HCC-TAG 2020 | Park City, Utah | February 27 – 29, 2020 | Conference Website

  • Poster: The HepQuant SHUNT Test of Global Liver Function and Physiology Identifies the Patients with Advanced Fibrosis or Compensated Cirrhosis Who are At-Risk for Hepatocellular Carcinoma
  • Poster: Deterioration in Liver Function after Liver-Directed Therapy for Hepatocellular Carcinoma Measured by Cholate Clearance

AASLD The Liver Meeting 2019: HepQuant attended the AASLD The Liver Meeting in Boston 2019, Nov. 8 – 12, 2019. The company presented the following poster:

Poster: “Functional Improvement Measured by a Reduction in HepQuant’s Disease Severity Index (DSI) After Sustained Viral Response (SVR) in Advanced Hepatitis C is Related to Severity of Hepatic Impairment as Determined by Baseline DSI.” Gregory T. Everson and Steve M. Helmke, HepQuant, LLC, Greenwood Village, CO; University of Colorado School of Medicine, Aurora, CO.

EASL International Liver Congress: Greg Everson, MD, and Brad Everson, HepQuant’s CEO and CBDO respectively, attended the EASL International Liver Congress, April 10-14, 2019 in Vienna, Austria.

Poster: A late breaker poster was released at EASL ILC 2019 discussing baseline and Day 85 HepQuant-SHUNT™ and Disease Severity Index (DSI) results from Intercept study 747-117 conducted in parallel to the Regenerate study. “Effect of Obeticholic Acid on Liver Function in Patients With Fibrosis due to NASH.” Naim Alkhouri (1), Gregory T. Everson (2), Steve Helmke (2), Jianfen Chen (3), Carl LaCerte (3), Michael Stenkilsson (3), Jeffrey E. Edwards (3). 1 Texas Liver Institute, University of Texas Health, San Antonio, TX; 2 HepQuant, Greenwood Village, CO; 3. Intercept Pharmaceuticals, Inc., San Diego, CA.

NASH-TAG Conference in Park City, Utah in January 2019

  • NASH-TAG 2019 (Poster 1): Title: Hepatobiliary and Metabolic Changes Occurring during Weight Loss and Subsequent Weight Maintenance in Obese Subjects: Implications for NASH Clinical Trials
  • NASH-TAG 2019 (Poster 2): Modeling the HepQuant STAT Test for Pre-screening NASH Subjects to Enrich Study Populations for the Desired Stage of Disease

AASLD Liver Meeting 2018: HepQuant attended the AASLD Liver Meeting in San Francisco, Nov. 9 – 13th. The company presented 2 posters:

  • Poster 1: “Defining and Monitoring Liver Disease in Chronic Hepatitis C: A Comparison of the Disease Severity Index (DSI) from the HepQuant SHUNT test with Ishak Fibrosis (IFS) from Liver Biopsy.” Everson GT, Helmke SM. Hepatology 2018;68:910A. Annotation: This study suggests that DSI may be more sensitive than IFS in measuring serial changes in disease in patients with chronic hepatitis C.
  • Poster 2: “Defining Disease Severity and Measuring Progression in Primary Sclerosing Cholangitis (PSC): A Comparison of the Disease Severity Index (DSI) from the HepQuant SHUNT Test with Serum Alkaline Phosphatase (Alk Phos).” Helmke SM, Everson GT. Hepatology 2018;1087A. Annotation: This study suggests that DSI may be more sensitive than Alk Phos in measuring serial changes in disease in patients with PSC.

NASH Summit 2018: “Identifying Potential Subjects for NASH Clinical Trials Using the HepQuant Quantitative Liver Tests” (Presentation) (Poster)

Discovery On Target (Boston, September 2018): “How HepQuant Tests May Aid Drug Development” (Presentation)

American Society of Clinical Oncology (ASCO) meeting (Jan. 19, 2018) highlighted a new potential use of HepQuant SHUNT – monitoring impact of cancer treatment on global liver function.

Poster: “Hepatic functional deterioration after locoregional therapy (LRT) for hepatocellular carcinoma (HCC) measured by hepatic cholate clearance: a pilot study”. Maarouf A Hoteit, MD (1); Christine Hsu, MD (1); Matthew H Levine, MD, PhD (2); Kimberly A. Forde ,MD (1); Kim Reiss, MD (3); Greg Nadolski, MD (4); Michael C. Soulen, MD (4); Laura E. Kron (1), Steve Helmke,PhD (5,6), Gregory T. Everson, MD (5,6); Edgar Ben-Josef, MD (7). 1 Division of Gastroenterology and Hepatology, 2 Division of Transplant Surgery, 3 Division of Hematology-Oncology, 4 Division of Interventional Radiology 7 Department of Radiation Oncology – all at the University of Pennsylvania, Philadelphia, PA. 5 Division of Gastroenterology and Hepatology, University of Colorado Denver, Aurora, CO. 6 Hepquant®, LLC, Denver, CO.

(Presentation Archives)